References
- Trussell J, Rodriguez G, Ellertson C. New estimates of the effectiveness of the Yuzpe regimen of emergency contraception. Contraception 1998;57:363–9
- Creinin MD, Schlaff W, Archer DF, et al. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 2006;108:1089–97
- Glasier A, Cameron ST, Fine PM, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomized non-inferiority trial and meta-analysis. Lancet 2010;375:555–62
- Croxatto HB, Brache V, Pavez M, et al. Pituitary-ovarian function following the standard levonorgestrel emergency contraceptive dose or a single 0.75-mg dose given on the days preceding ovulation. Contraception 2004;70:442–50
- Brache V, Cochon L, Jesam C, et al. Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture. Hum Reprod 2010;25:2256–63
- Wilcox AJ, Dunson D, Baird DD. The timing of the “fertile window” in the menstrual cycle: day specific estimates from a prospective study. Br Med J 2000;321:1259–62
- Brache V, Cochon L, Deniaud M, Croxatto H. Ulipristal acetate prevents ovulation more effectively than levonorgestrel – analysis of pooled data from three randomized trials of emergency contraception. Contraception 2013;88:611–8
- Levy DP, Jager M, Kapp N, Abitbol JL. Ulipristal acetate for emergency contraception: postmarketing experience after use by more than 1 million women. Contraception 2014;89:431–3
- Hunter C, Ginde S, van Santen M, et al. Ulipristal Acetate 30 mg for emergency contraception is safe and effective both in adolescents and adult women: results from an International multicentre observational study. Free Communication 01.6. Eur J Contracept Reprod Health Care 2014;19:S67–90
- Thomas CM, Cameron S. Can we reduce costs and prevent more unintended pregnancies? A cost of illness and cost-effectiveness study comparing two methods of EHC. BMJ Open 2013;3:e003815